Autoantibodies recognizing the 27 carboxy-terminal amino acids of calpastatin are associated with secondary Sjögren syndrome in systemic lupus erythematosus

Abstract

The objective of this study was to determine in systemic lupus erythematosus (SLE) the prevalence and clinical significance of anticalpastatin antibodies (ACAST), an autoantibody population previously detected in sera from patients with various connective tissue diseases. Eighty-four patients with SLE (mean age: 30 years at diagnosis, females 77) that fulfilled ACR criteria were included in the study retrospectively. Several clinical and biological data were collected. ACAST were detected by a solid-phase enzyme linked immunosorbent assay (ELISA) using as antigen a synthetic peptide corresponding to the 27 C-terminal amino acids of calpastatin (CAST-C27). The prevalence of ACAST-C27 was 13% (11/84) in SLE patients. No correlation was found between the presence of ACAST-C27 and clinical manifestations such as thrombosis and vasculitis. Furthermore, no correlation was observed with the presence of antiphospholipid antibodies (APL). However, we found a statistically significant association between the presence of ACAST-C27 and that of secondary Sjögren syndrome (P = 0.01). The conclusion is ACAST-C27 are not associated with thrombosis in SLE patients. The association observed between ACAST-C27 and secondary Sjögren syndrome suggests that ACAST-C27 might be useful in discriminating a clinical subgroup of SLE patients.

Keywords

anti-calpastatin antibodies Sjögren syndrome systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

Mason LJ , Isenberg DA. Immunopathogenesis of SLE . Baillières’s Clin Rheumatol 1998; 12: 385-403 .

Casciola-Rosen LA , Anhalt G , Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes . J Exp Med 1994; 179: 1317-1330 .

Von Mühlen CA , Chan EKL , Anglés-Cano E , Mamula MJ , Garcia-De La Torre I , Fritzler MJ. Advances in autoantibodies in SLE . Lupus 1998; 7: 507-514 .

Després N , Talbot G , Plouffe B , Boire G , Ménard HA. Detection and expression of a cDNA clone that encodes a polypeptide containing two inhibitory domains of human calpastatin and its recognition by rheumatoid arthritis sera . J Clin Invest 1995; 95: 1891-1896 .

Mimori T , Suganuma K , Tanami Y et al. Autoantibodies to calpastatin (an endogenous inhibitor for calcium-dependent neutral protease, calpain) in systemic rheumatic diseases . Proc Natl Acad Sci USA 1995; 92: 7267-7271 .

Croall DE , Demartino GN. Calcium-activated neutral protease (calpain) system: structure, function, and regulation . Physiol Rev 1991; 71: 813-847 .

Moore JC , Murphy WG , Kelton JG. Calpain proteolysis of von Willebrand factor enhances its binding to platelet membrane glycoprotein IIb/IIIa: an explanation for platelet aggregation in thrombotic thrombocytopenic purpura . Br J Haematol 1990; 74: 457-464 .

Squier MKT , Miller ACK , Malkinson AM , Cohen JJ. Calpain activation in apoptosis . J Cell Physiol 1994; 159: 229-237 .

Squier MKT , Sehnert AJ , Sellins KS , Malkinson AM , Takano E , Cohen JJ. Calpain and calpastatin regulate neutrophil apoptosis . J Cell Physiol 1999; 178: 311-319 .

10.

Schlosser U , Lackner KJ , Scheckenhofer C , Schmitz G. Calpastatin autoantibodies: detection, epitope mapping, and development of a specific peptide ELISA . Clin Chem 1996; 42: 1250-1256 .

11.

Schlosser U , Lackner KJ , Scheckenhofer C et al. Autoantibodies against the protease inhibitor calpastatin: a new risk factor for venous thrombosis ? Thromb Haemost 1997; 77: 11-13 .

12.

Lackner KJ , Schlosser U , Lang B , Schimtz G. Autoantibodies against human calpastatin in rheumatoid arthritis: epitope mapping and analysis of patient sera . Br J Rheumatol 1998; 37: 1164-1171 .

13.

Vittecoq O , Salle V , Jouen-Beades F et al. Autoantibodies to the 27 C-terminal amino acids of calpastatin are detected in a restricted set of connective tissue diseases and may be useful for diagnosis of rheumatoid arthritis in community cases of very early arthritis . Rheumatology 2001; 40: 1126-1134 .

14.

Tan EM , Cohen AS , Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum 1982; 25: 1271-1277 .

15.

Hochberg M. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum 1997; 40: 1725-1725 .

16.

Bombardier C , Gladmann DD , Urowitz MB , Caron D , Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients . Arthritis Rheum 1992; 35: 630-640 .

17.

Wilson WA , Gharavi AE , Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome . Arthritis Rheum 1999; 42: 1309-1311 .

18.

Vitali C , Bombardieri S , Moutsopoulos HM et al. Preliminary criteria for the classification of Sjögren’s syndrome. Results of a prospective concerted action supported by the European Community . Arthritis Rheum 1993; 36: 340-347 .

19.

Harris EN. Special report. The second international anti-cardiolipin standardization workshop/the Kingston anti-phospholipid antibody study (KAPS) group . Am J Clin Path 1990; 94: 476-484 .

20.

Cervera R , Khamashta MA , Font J et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus . Medicine (Baltimore) 1993; 72: 113-124 .

21.

Cervera R , Font J , Pare C et al. Cardiac disease in systemic lupus erythematosus: prospective study of 70 patients . Ann Rheum Dis 1992; 51: 156-159 .

22.

Iwaki-Egawa S , Matsuno H , Yudoh K et al. High diagnostic value of anticalpastatin autoantibodies in rheumatoid arthritis detected by ELISA using human erythrocyte calpastatin as antigen . J Rheumatol 2004; 31: 17-22 .

23.

Bolstad AI , Jonsson R. The role of apoptosis in Sjögren’s syndrome . Ann Med Interne 1998; 149: 25-29 .

24.

Robinson CP , Yamachika S , Alford CE et al. Elevated levels of cysteine protease activity in saliva and salivary glands of the nonobese diabetic (NOD) mouse model for Sjögren syndrome . Proc Natl Acad Sci USA 1997; 94: 5767-5771 .